Institutes
Refine
Year of publication
- 2020 (245) (remove)
Document Type
- Article (196)
- Preprint (39)
- Doctoral Thesis (10)
Language
- English (245) (remove)
Has Fulltext
- yes (245)
Is part of the Bibliography
- no (245)
Keywords
- COVID-19 (9)
- SARS-CoV-2 (5)
- bladder cancer (4)
- Aortic stenosis (3)
- Hypoxia (3)
- Inflammation (3)
- Macrophages (3)
- Mortality (3)
- Peri-implantitis (3)
- Postural control (3)
- Quality of life (3)
- Stroke (3)
- TAVI (3)
- Treatment (3)
- inflammation (3)
- macrophage (3)
- miRNA (3)
- Ataxia telangiectasia (2)
- Bibliometrics (2)
- Clinical decision support systems (2)
- Computer-assisted diagnosis (2)
- EEG (2)
- Endoscopy (2)
- Epidemiology (2)
- Epilepsy (2)
- Genetics (2)
- Glioma (2)
- Healthy adults (2)
- Long-term potentiation (2)
- Outcome (2)
- Pneumonia (2)
- Rare diseases (2)
- Seizure (2)
- Wearable cardioverter-defibrillator (2)
- Women (2)
- bibliometrics (2)
- cancer (2)
- cerebral hemorrhage (2)
- cerebral venous thrombosis (2)
- coagulopathy (2)
- drug resistance (2)
- mTOR (2)
- obesity (2)
- patient blood management (2)
- polytrauma (2)
- post-translational modifications (2)
- psoriasis (2)
- public health (2)
- quality of life (2)
- sphingosine 1-phosphate (2)
- spinal dural leaks (2)
- stroke (2)
- sulforaphane (2)
- superficial siderosis (2)
- thymus (2)
- 3D printing (1)
- 3D rapid prototyping (1)
- 4-fluoroamphetamine (1)
- AAA+ disaggregase (1)
- ADAMTS13 (1)
- ADGRE1 (1)
- ADHD (1)
- AML (1)
- ARDS (1)
- ASPECTS (1)
- Abductor pollicis longus (1)
- Ablation (1)
- Abrasion (1)
- Abusive head trauma (AHT) (1)
- Accumulated degree days (1)
- Acute appendicitis (1)
- Acute elbow dislocation (1)
- Acute lymphoblastic leukemia (1)
- Acute-on-chronic subdural hematoma (1)
- Adherence (1)
- Administrative claims data (1)
- Adverse drug reaction (1)
- Age determination (1)
- Albumin ratio (1)
- Allogeneic (1)
- Amisulpride (1)
- Amitriptyline (1)
- Anal cancer (1)
- Anandamide (1)
- Anatomy (1)
- Anderson–Fabry (1)
- Angiogenesis (1)
- Animal model (1)
- Anti-inflammatory (1)
- Anti-rheumatic agents (1)
- Anticholinergic (1)
- Anticoagulant (1)
- Anticoagulation (1)
- Aortic input function (1)
- Appendectomy (1)
- Arrhythmia syndromes (1)
- Arthroplasty (1)
- Artificial intelligence (1)
- Ataxia score (1)
- Atm (1)
- Atrial fibrillation (1)
- Attention deficit (1)
- Autism spectrum disorder (1)
- Autoimmune vasculopathy (1)
- Autologous biomaterial (1)
- Axiography (1)
- BEZ235 (1)
- BMC (1)
- BMI (1)
- Bacterial abundance (1)
- Balloon-expandable TAVI (1)
- Benign enlargement of the subarachnoid spaces (BESS) (1)
- Bioenergetics (1)
- Biopsy (1)
- Bladder cancer (1)
- Bleeding (1)
- Blocked occlusion (1)
- Body modification (1)
- Bone defect (1)
- Bone regeneration (1)
- Bone remodelling (1)
- Bone substitute (1)
- Bone tissue engineering (1)
- Brain asymmetry (1)
- Brain injuries (1)
- Brain tumor surgery (1)
- Breast cancer survivers (1)
- Burden of illness (1)
- CAD/CAM (1)
- CCL2 (1)
- CD34 + cells (1)
- CD44 (1)
- CDI (1)
- CEBPD (1)
- COMP (1)
- COVID 19 pandemic (1)
- Calpain (1)
- Cancer (1)
- Capnography (1)
- Cardiac arrest (1)
- Cardiology (1)
- Cardiovascular magnetic resonance (1)
- Caspase-8 (1)
- Cell death and immune response (1)
- Cerebral hypoperfusion (1)
- Cerebrospinal fluid (1)
- Cerebrovascular disorders (1)
- Cezanne (1)
- Chemoradiotherapy (1)
- Child (1)
- Child abuse (1)
- Chronic inflammation (1)
- Classification (1)
- Clavien–Dindo classification (1)
- Climate inequity (1)
- Clinical genetics (1)
- Clinical trial (1)
- Coagulation (1)
- Cognition (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Collagen-based biomaterial (1)
- Colonic neoplasms (1)
- Complications (1)
- Compression stocking (1)
- Computational biophysics (1)
- Confinement (1)
- Congenital diaphragmatic hernia (1)
- Connectivity (1)
- Conservative treatment (1)
- Constitution (1)
- Control (1)
- Cooperation (1)
- Copy number (1)
- Coronary artery disease (1)
- Cortical degeneration (1)
- Cortical thickness (1)
- Craniomaxillofacial injuries (1)
- Critical care (1)
- Critical size (1)
- Cryoelectron microscopy (1)
- Cystic fibrosis (1)
- Cytokines (1)
- DBS (1)
- DNA methylation (1)
- DST (1)
- Data science (1)
- Decontamination (1)
- Deep vein thrombosis (1)
- Defibrillation (1)
- Density equalizing mapping (1)
- Density-equalizing mapping (1)
- Dental air (1)
- Dental casts (1)
- Dental implant (1)
- Dental implants (1)
- Dental practice (1)
- Dental students (1)
- Depression (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diagnostic error (1)
- Differential diagnosis (1)
- Disaster victim identification (1)
- Disintegration (1)
- Distribution limits (1)
- Dopamine (1)
- Double-blind placebo-controlled trial (1)
- Drug susceptibility testing (1)
- Dural onlays (1)
- Dysphagia (1)
- EGFR (1)
- EGFRvIII mutation (1)
- EMR1 (1)
- EMT (1)
- Edoxaban (1)
- Education (1)
- Ejection fraction (1)
- Elderly (1)
- Electrical stimulation (1)
- Emergency treatment (1)
- Endocrinology (1)
- Endometrial carcinoma (1)
- Endothelial cells (1)
- Endothelial protein C receptor (1)
- Energy metabolism (1)
- Enterobacteriaceae (1)
- Epidural abscess (1)
- Evaluation (1)
- Evidence-based dentistry (1)
- Evidence-based medicine (1)
- Exercise challenge (1)
- Exercise-induced asthma (1)
- Exhaled nitric oxide (1)
- F4/80 (1)
- FBK-R23 (1)
- FEV1 (1)
- FHIR (1)
- FIH1 (1)
- FTMT (1)
- Fasting (1)
- Feedback (1)
- Female subjects (1)
- Ferritinophagy (1)
- Ferroptosis (1)
- Finevo (1)
- Fluid therapy (1)
- Forced expiratory volume in 1 s (1)
- Forensic entomology (1)
- Forensic examination (1)
- Fracture (1)
- Fracture type (1)
- Functional characterization (1)
- G-CSF (1)
- GLA deficiency (1)
- Gait analysis (1)
- Gastroschisis (1)
- Gene regulation (1)
- General practice (1)
- Genetic heart disease (1)
- Genetic syndromes (1)
- Geographical disparities (1)
- Global warming (1)
- Graph theory (1)
- Greenhouse effect (1)
- Guided bone regeneration (GBR) (1)
- Guided tissue regeneration (GTR) (1)
- HADS (1)
- HDAC and BET inhibitor (1)
- HDAC4 (1)
- HIV (1)
- HOSO (1)
- Haematocrit (1)
- Health care (1)
- Healthcare costs (1)
- Healthcare resource utilization (1)
- Heart failure (1)
- Heat shock protein 27 (1)
- Hemispheric specialization (1)
- Hemodynamics (1)
- Heterogeneity (1)
- High oblique sagittal osteotomy (1)
- Hippocampal excitability (1)
- Hippocampus (1)
- Histological analysis (1)
- HoLEP (1)
- Human behaviour (1)
- Hyperactivity (1)
- Hyperscanning (1)
- Hypoxia-inducible factor-1α (HIF-1α) (1)
- ICAM-1 (1)
- ICD (1)
- IDH mutation (1)
- IL-1β (1)
- ISR (1)
- Identification (1)
- Identifikation (1)
- Identifizierung von Katastrophenopfern (1)
- Immunohistochemistry (1)
- Immunology (1)
- Immunomodulatory agents (1)
- Implant osseointegration (1)
- Imrt (1)
- In vitro (1)
- In vivo (1)
- Inducible nitric oxide synthase (iNOS) (1)
- Induction chemotherapy (1)
- Infections (1)
- Inflammatory pattern (1)
- Injury Severity Score (ISS) (1)
- Innate immunity (1)
- Integrated Pulmonary Index (1)
- Integration (1)
- IntelliCage (1)
- Interoperability (1)
- Interposition (1)
- Interstitial pneumonia (1)
- Interview (1)
- Intravenous antibiotic therapy (1)
- Iron (1)
- Isocitrate dehydrogenase (1)
- JNK (1)
- Joint actions (1)
- Joint loading (1)
- K-homology RNA-binding domain (1)
- Kidney diseases (1)
- Körpermodifizierung (1)
- L-DOPA (1)
- Language delay (1)
- Lennox-Gastaut syndrome (1)
- Lockdown (1)
- Longchain polyunsaturated fatty acids (1)
- Low-dose radiation therapy (1)
- Lung cancer (1)
- Lung development (1)
- Lung function (1)
- Lung ultrasound (1)
- Lysophosphatidic acids (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MRI (1)
- MS (1)
- Machine learning (1)
- Machine-learning (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Management (1)
- Mass disaster (1)
- Massenkatastrophe (1)
- Maxillofacial surgery (1)
- Mean erythrocyte volume (1)
- Medical research (1)
- Meta-analysis (1)
- Metabolic diseases (1)
- Michael acceptor (1)
- Microparticles (1)
- Mitochondrial dysfunction (1)
- Mobilization (1)
- Molecular autopsy (1)
- Molecular neuroscience (1)
- Monetary incentive delay (1)
- Mongolian spot (1)
- Monitoring (1)
- Monocytes (1)
- Morbidity (1)
- Morphologie (1)
- Morphology (1)
- Multidrug-resistance (1)
- Multimedication (1)
- Multimorbidity (1)
- Multiparametric MRI (1)
- Multiplate (1)
- Multiple-indication review (1)
- Myocardial infarction (MI) (1)
- Myocardial injury (1)
- Myocardial perfusion (1)
- NAFLD (1)
- NCOA4 (1)
- NCoR1 (1)
- NF-κB pathway (1)
- NIRS (1)
- NLRP3 inflammasomes (1)
- NTM (1)
- Negative appendectomy rate (1)
- Nek1 (1)
- Neonatal surgery outcome (1)
- Neurodegeneration (1)
- Neuron (1)
- Neurosurgery (1)
- Neurotransmitter (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- Next-generation sequencing (1)
- Non-abusive head trauma (NAHT) (1)
- Non-apoptotic functions (1)
- Non-tuberculous mycobacteria (1)
- Non-vitamin K antagonist oral anticoagulants (1)
- Normative modeling (1)
- Number of platelets (1)
- OSA (1)
- OTU domain-containing protein 7B (OTUD7B) (1)
- Omphalocele (1)
- Oncology (1)
- Oral anticoagulation (1)
- Orthognathic surgery (1)
- Osteoarthritis (1)
- Outcomes (1)
- Ovarian cancer treatment (1)
- Overwintering (1)
- PI3K/mTor inhibition (1)
- PV loop (1)
- PWI (1)
- Paediatric trauma patients (1)
- Pain (1)
- Parasympathetic (1)
- Patient blood management (1)
- Patient outcome assessment (1)
- Patient safety (1)
- Patterns of care (1)
- Pelvic (1)
- Percutaneous endoscopic gastrostomy (1)
- Periodontitis grades B and C (1)
- Periprocedural anticoagulation (1)
- Perrault syndrome (1)
- Phalangeal fractures (1)
- Phase I clinical trial (1)
- Phenotypic plasticity (1)
- Physical activity (1)
- Platelet-rich fibrin (1)
- Polygenic risk score (1)
- Polypharmacy (1)
- Post mortem interval (1)
- Pressure distribution (1)
- Pressure measuring plate (1)
- Prevalence (1)
- Prevention (1)
- Primary health care (1)
- Procedural skills (1)
- Prostate cancer (1)
- Pseudoprogression (1)
- Psychology (1)
- Pteridine (1)
- Pulmonary edema (1)
- Pulmonary embolism (1)
- Pulmonary hypertension (1)
- Pulmonary hypoplasia (1)
- Qualitative research (1)
- Quantitative (q)T2 mapping (1)
- Quantitative magnetic resonance imaging (1)
- Quantra (1)
- Questionnaire (1)
- Quinolones (1)
- RIPK1 (1)
- RNA chaperone (1)
- Radiomics (1)
- Ramadan (1)
- Refractory ALL (1)
- Refractory AML (1)
- RegJoint™ (1)
- Regeneration (1)
- Registries (1)
- Regret (1)
- Reliability (1)
- Rescue medication (1)
- Research investment (1)
- Respiratory distress syndrome (1)
- Retinal diseases (1)
- Retinoic acid (1)
- Return to work (1)
- Reward (1)
- Rheumatoid arthritis (1)
- Risk-stratification (1)
- S1P receptors (1)
- SCA2 (1)
- SCN5A (1)
- SEAP (1)
- SIDS (1)
- SLUG (1)
- SNORD95 (1)
- Safety (1)
- Saudi Arabia (1)
- Second donation (1)
- Self-expandable TAVI (1)
- Serious injured children (1)
- Serum biomarker (1)
- Sex (1)
- Sharp injuries (1)
- Shoulder luxation (1)
- Side effects (1)
- Signal intensity (1)
- Signs and symptoms (1)
- Social brain (1)
- Social differences (1)
- Socio-economic analysis (1)
- Socioeconomic analysis (1)
- Socioeconomic indices (1)
- Spine fractures (1)
- Spinocerebellar ataxia type 2 (1)
- Stage at presentation (1)
- Standard dataset (1)
- Standard reference values (1)
- Standard value (1)
- Status epilepticus (1)
- Stem cell (1)
- Sterols (1)
- Striatum (1)
- Stroke genetics (1)
- Sub-zero exposure (1)
- Sudden death (1)
- Sudden infant death syndrome (1)
- Surgery (1)
- Surgical therapy (1)
- Survey (1)
- Suspension (1)
- Swallowing (1)
- Sympathetic (1)
- Synaptic transmission (1)
- T cell receptor (1)
- T cells (1)
- T-cell receptor (1)
- T2 (1)
- TAMs (1)
- TGF-β (1)
- TGR(mREN2)27 (1)
- TRIMs (1)
- Targeted sequencing (1)
- Test assay (1)
- Therapies (1)
- Thrombotic thrombocytopenic purpura (1)
- Thumb carpometacarpal joint osteoarthritis (1)
- Tissue engineering (1)
- Tocilizumab (1)
- Total hip arthroplasty (1)
- Touchscreen (1)
- Transcription regulation (1)
- Transcriptional regulatory elements (1)
- Transfusion (1)
- Transfusion practice (1)
- Transgenic mice (1)
- Translation proteomics (1)
- TraumaRegister DGU® (TR-DGU) (1)
- Treatment effectiveness (1)
- Treatment rates (1)
- Treg cell (1)
- Tumor microenvironment (1)
- Type 2 diabetes (1)
- UBA domain (1)
- Ubiquitin ligase (1)
- Uncertainty (1)
- Undergraduate education (1)
- Upper body posture (1)
- VIM (1)
- Validation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Venous thromboembolism (1)
- Ventricular arrhythmia (1)
- Ventricular arrhythmias (1)
- Videorasterstereography (1)
- Volume therapy (1)
- Volunteer donor (1)
- Watertight Dural closure (1)
- Western diet (1)
- Winter survival (1)
- Wound healing (1)
- Wounds (1)
- [18F]FET PET (1)
- activated clotting time measurement (1)
- adaptation (1)
- adhesion (1)
- adiabatic saturation (1)
- adipose-derived mesenchymal stem/stromal cells (1)
- adult (1)
- aging (1)
- alcoholic hepatitis (1)
- algorithm (1)
- allogeneic donor (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha power (1)
- alpha-galactosidase A deficiency (1)
- alternative matrices (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia walk-in clinic (1)
- angiokeratoma diffuse (1)
- anti-inflammatory drug (1)
- aortic stenosis (1)
- apoptosis (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- aspiration (1)
- auditory fMRI (1)
- bacteria (1)
- bio imaging (1)
- bioactive lipids (1)
- bioavailability (1)
- bioluminescence (1)
- bipolar disorder (1)
- blinatumomab (1)
- blood pressure (1)
- blood transfusion (1)
- brain (1)
- brain shift (1)
- brain tumor (1)
- breast cancer (1)
- bypass (1)
- caesarean scar (1)
- caesarean section (1)
- cancer information (1)
- cancer specific survival (1)
- cardiothoracic surgery (1)
- cell death (1)
- ceramides (1)
- cerumen (1)
- cervical cancer (1)
- chemoprotection (1)
- chemoresistance (1)
- chemotaxis (1)
- chemotherapy (1)
- clinical immunology (1)
- coagulation (1)
- cognitive aging (1)
- colorectal cancer (1)
- colorectal cancer (CRC) (1)
- contamination (1)
- cortex (1)
- covalent drugs (1)
- curcumin (1)
- cyclin Y (1)
- cyclooxygenase 2 (1)
- cytokine storm (1)
- cytotoxic lymphocytes (1)
- cytotoxicity (1)
- data science (1)
- debris (1)
- deferred treatment (1)
- delayed treatment (1)
- delirium (1)
- demineralized bone matrix (1)
- dentoalveolar surgery (1)
- deubiquitinase (DUB) (1)
- deubiquitylation (deubiquitination) (1)
- donor safety (1)
- drug abstinence (1)
- dysphagia (1)
- early detection (1)
- electronic adherence measurement (1)
- electrophilic fatty acids (1)
- epidemics (1)
- epidemiology (1)
- epilepsy (1)
- episodic memory (1)
- epithelial-to-mesenchymal transition (EMT) (1)
- essential tremor (1)
- euthymic (1)
- everolimus (1)
- evolution (1)
- exercise (1)
- experimental pain models (1)
- fMRI (1)
- flow cytometry (1)
- focal cortical dysplasia (1)
- fractionation (1)
- fragile-X-associated tremor-ataxia syndrome (1)
- fronto-temporal lobar dementia (1)
- fronto-temporal-lobar-dementia (1)
- functional connectivity (1)
- gene regulation (1)
- geriatric patients (1)
- glioblastoma (1)
- glioblastoma cells (1)
- glioma (1)
- graph theory (1)
- growth (1)
- hemorrhage (1)
- hepatic stellate cells (1)
- hepatitis C virus (HCV) (1)
- hepatocellular cancer (1)
- hereditary dystopic lipidosis (1)
- high-throughput screening (1)
- hippocampus (1)
- histological outcomes (1)
- human genomics (1)
- hybrid abutment (1)
- hydroxylation (1)
- hypoxia (1)
- imaging (1)
- immune checkpoint (1)
- immune defense (1)
- immune response (1)
- immunity (1)
- immuno-oncotherapy (1)
- immunosuppression (1)
- immunotherapy (1)
- in vitro models (1)
- infection (1)
- inferior frontal gyrus (1)
- innate immunity (1)
- inositol signaling (1)
- integrated stress response (1)
- integrin (1)
- integrins (1)
- inter-individual variability (1)
- interferon type III (1)
- investigational (1)
- inflammation (1)
- iron deficiency (1)
- joint contact forces (1)
- knee adduction moment (1)
- lichen extracts (1)
- lipoxin A4 (1)
- liquid chromatography–mass spectrometry (1)
- liver fibrosis (1)
- long-term potentiation (1)
- long-term success (1)
- lymphocytes (1)
- machine learning (1)
- medication adherence rate (1)
- mental distress (1)
- mesenchymal stromal cells (1)
- mesenchymal stromal/stem cells (1)
- metabolism (1)
- miR-142-3p (1)
- miR-181 (1)
- miR-6862-5p (1)
- microRNA (1)
- mid-IR spectroscopy (1)
- migration (1)
- minimal residual disease (1)
- mitochondria (1)
- mitochondrial antiviral signaling protein (MAVS) (1)
- mitochondrial metabolism (1)
- mitochondrial morphology (1)
- mixed lineage kinase domain-like (1)
- molecular adaptation (1)
- molecular biology (1)
- molecular dynamics (1)
- monotype abutment (1)
- monsoon (1)
- mortality analysis (1)
- mortality risk (1)
- musculoskeletal inflammation (1)
- musculoskeletal modeling (1)
- neural oscillations (1)
- neurexin (1)
- next-generation sequencing (1)
- nitroalkylation (1)
- noninvasive blood glucose analysis (1)
- nuclear magnetic resonance (NMR) (1)
- nutrient endocytosis (1)
- oncogenic signaling (1)
- oral and maxillofacial surgery (1)
- orthopaedic patients (1)
- osteoarthritis (1)
- outside-in signaling (1)
- pain (1)
- patient’s decree (1)
- perceptual closure (1)
- pericytes (1)
- periodontal risk factors (1)
- photothermal detection (1)
- placenta (1)
- planimetric measurement (1)
- plasma (1)
- pneumocystis (1)
- point of care (1)
- poly(A)-tail (1)
- portal hypertension (1)
- post-caesarean uterus (1)
- post-exercise hypotension (1)
- posterior fossa tumor (1)
- postmonsoon (1)
- posttranslational modification (PTM) (1)
- precision weighting (1)
- predictive coding (1)
- prevalence (1)
- prognosis (1)
- prognostic marker (1)
- proliferation (1)
- prostate cancer (1)
- protease inhibitor (1)
- protein-protein interaction (1)
- proteostasis (1)
- psoriatic arthritis (1)
- qRT-PCR (1)
- quantum cascade laser (QCL) (1)
- radical prostatectomy (1)
- radiosensitization (1)
- rat femur critical size defect (1)
- regulatory T cell (1)
- regulatory T helper cells (1)
- relaxometry (1)
- renal cell carcinoma (1)
- renal transplantation (1)
- replicative fitness (1)
- resistance mutation (1)
- resolution of inflammation (1)
- reticulocyte haemoglobin (1)
- risk factor (1)
- risk factors (1)
- rotational thromboelastometry (1)
- scanner noise (1)
- schizophrenia (1)
- screening (1)
- selection (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured (1)
- signaling (1)
- simulation training (1)
- sonography (1)
- sparse imaging (1)
- spatial learning (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine kinase (1)
- sphingosine-1-phosphate (1)
- spreading (1)
- starvation (1)
- steady-state condition (1)
- steatosis (1)
- stem cell transplantation (1)
- stem cells (1)
- stress (1)
- structure constraints (1)
- supportive periodontal therapy (1)
- survival (1)
- swallowing (1)
- synaesthesia (1)
- synaptic plasticity (1)
- tauopathies (1)
- tauopathy (1)
- thrombosis (1)
- tooth loss (1)
- total hip replacement (1)
- tracking (1)
- transcriptome (1)
- transferrin (1)
- translatome (1)
- transplantation (1)
- trauma registry (1)
- traumaticbraininjury(TBI) (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase receptor signaling (1)
- ubiquitin (1)
- ubiquitin hydrolase (1)
- ultrasonic cleaning (1)
- unconventional T cell (1)
- uterine wall (1)
- variable silent delay (1)
- ventralis intermedius nucleus (1)
- vertical transmission (1)
- viruses (1)
- vitamin k antagonists (1)
- waiting time (1)
- walking (1)
- white matter hyperintensity (1)
- xenograft (1)
- fibrogenesis (1)
- fingolimod (1)
Institute
- Medizin (245)
- Biowissenschaften (3)
- Ernst Strüngmann Institut (3)
- Frankfurt Institute for Advanced Studies (FIAS) (3)
- MPI für Hirnforschung (3)
- Psychologie (2)
- Biochemie und Chemie (1)
- Biochemie, Chemie und Pharmazie (1)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (1)
- Informatik und Mathematik (1)
The coronavirus disease 2019 COVID-19 pandemic is rapidly spreading worldwide and is becoming a major public health crisis. Increasing evidence demonstrates a strong correlation between obesity and the COVID-19 disease. We have summarized recent studies and addressed the impact of obesity on COVID-19 in terms of hospitalization, severity, mortality, and patient outcome. We discuss the potential molecular mechanisms whereby obesity contributes to the pathogenesis of COVID-19. In addition to obesity-related deregulated immune response, chronic inflammation, endothelium imbalance, metabolic dysfunction, and its associated comorbidities, dysfunctional mesenchymal stem cells/adipose-derived mesenchymal stem cells may also play crucial roles in fueling systemic inflammation contributing to the cytokine storm and promoting pulmonary fibrosis causing lung functional failure, characteristic of severe COVID-19. Moreover, obesity may also compromise motile cilia on airway epithelial cells and impair functioning of the mucociliary escalators, reducing the clearance of severe acute respiratory syndrome coronavirus (SARS-CoV-2). Obese diseased adipose tissues overexpress the receptors and proteases for the SARS-CoV-2 entry, implicating its possible roles as virus reservoir and accelerator reinforcing violent systemic inflammation and immune response. Finally, anti-inflammatory cytokines like anti-interleukin 6 and administration of mesenchymal stromal/stem cells may serve as potential immune modulatory therapies for supportively combating COVID-19. Obesity is conversely related to the development of COVID-19 through numerous molecular mechanisms and individuals with obesity belong to the COVID-19-susceptible population requiring more protective measures.
Objective: Spinal epidural abscess (SEA) is a severe and life-threatening disease. Although commonly performed, the effect of timing in surgical treatment on patient outcome is still unclear. With this study, we aim to provide evidence for early surgical treatment in patients with SEA.
Methods: Patients treated for SEA in the authors' department between 2007 and 2016 were included for analysis and retrospectively analyzed for basic clinical parameters and outcome. Pre- and postoperative neurological status were assessed using the American Spinal Injury Association Impairment Scale (AIS). The self-reported quality of life (QOL) based on the Short-Form Health Survey 36 (SF-36) was assessed prospectively. Surgery was defined as "early", when performed within 12 hours after admission and "late" when performed thereafter. Conservative therapy was preferred and recommend in patients without neurological deficits and in patients denying surgical intervention.
Results: One hundred and twenty-three patients were included in this study. Forty-nine patients (39.8%) underwent early, 47 patients (38.2%) delayed surgery and 27 (21.9%) conservative therapy. No significant differences were observed regarding mean age, sex, diabetes, prior history of spinal infection, and bony destruction. Patients undergoing early surgery revealed a significant better clinical outcome before discharge than patients undergoing late surgery (p=0.001) and conservative therapy. QOL based on SF-36 were significantly better in the early surgery cohort in two of four physical items (physical functioning and bodily pain) and in one of four psychological items (role limitation) after a mean follow-up period of 58 months. Readmission to the hospital and failure of conservative therapy were observed more often in patients undergoing conservative therapy.
Conclusion: Our data on both clinical outcome and QOL provide evidence for early surgery within 12 hours after admission in patients with SEA.
Background: The treatment of severely injured patients, especially in older age, is complex, and based on strict guidelines. Methods: We conducted a retrospective study by analyzing our internal registry for mortality risk factors in deceased trauma patients. All patients that were admitted to the trauma bay of our level-1-trauma center from 2014 to 2018, and that died during the in-hospital treatment, were included. The aim of this study was to carry out a quality assurance concerning the initial care of severely injured patients. Results: In the 5-year period, 135 trauma patients died. The median (IQR) age was 69 (38–83) years, 71% were male, and the median (IQR) Injury Severity Score (ISS) was 25 (17–34) points. Overall, 41% of the patients suffered from severe traumatic brain injuries (TBI) (AIShead ≥ 4 points). For 12.7%, therapy was finally limited owing to an existing patient’s decree; in 64.9% with an uncertain prognosis, a ‘therapia minima’ was established in consensus with the relatives. Conclusion: Although the mortality rate was primarily related to the severity of the injury, a significant number of deaths were not exclusively due to medical reasons, but also to a self-determined limitation of therapy for severely injured geriatric patients. The conscientious documentation concerning the will of the patient is increasingly important in supporting medical decisions.
Background: The epidermal growth factor receptor (EGFR) signaling pathway is genetically activated in approximately 50% of glioblastomas (GBs). Its inhibition has been explored clinically but produced disappointing results, potentially due to metabolic effects that protect GB cells against nutrient deprivation and hypoxia. Here, we hypothesized that EGFR activation could disable metabolic adaptation and define a GB cell population sensitive to starvation.
Methods: Using genetically engineered GB cells to model different types of EGFR activation, we analyzed changes in metabolism and cell survival under conditions of the tumor microenvironment.
Results: We found that expression of mutant EGFRvIII as well as EGF stimulation of EGFR-overexpressing cells impaired physiological adaptation to starvation and rendered cells sensitive to hypoxia-induced cell death. This was preceded by adenosine triphosphate (ATP) depletion and an increase in glycolysis. Furthermore, EGFRvIII mutant cells had higher levels of mitochondrial superoxides potentially due to decreased metabolic flux into the serine synthesis pathway which was associated with a decrease in the NADPH/NADP+ ratio.
Conclusions: The finding that EGFR activation renders GB cells susceptible to starvation could help to identify a subgroup of patients more likely to benefit from starvation-inducing therapies.
Background: Unwanted anticholinergic effects are both underestimated and frequently overlooked. Failure to identify adverse drug reactions (ADRs) can lead to prescribing cascades and the unnecessary use of over-thecounter products. The objective of this systematic review and meta-analysis is to explore and quantify the frequency and severity of ADRs associated with amitriptyline vs. placebo in randomized controlled trials (RCTs) involving adults with any indication, as well as healthy individuals. Methods: A systematic search in six electronic databases, forward/backward searches, manual searches, and searches for Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval studies, will be performed. Placebo-controlled RCTs evaluating amitriptyline in any dosage, regardless of indication and without restrictions on the time and language of publication, will be included, as will healthy individuals. Studies of topical amitriptyline, combination therapies, or including <100 participants, will be excluded. Two investigators will screen the studies independently, assess methodological quality, and extract data on design, population, intervention, and outcomes ((non-)anticholinergic ADRs, e.g., symptoms, test results, and adverse drug events (ADEs) such as falls). The primary outcome will be the frequency of anticholinergic ADRs as a binary outcome (absolute number of patients with/without anticholinergic ADRs) in amitriptyline vs. placebo groups. Anticholinergic ADRs will be defined by an experienced clinical pharmacologist, based on literature and data from Martindale: The Complete Drug Reference. Secondary outcomes will be frequency and severity of (non-)anticholinergic ADRs and ADEs. The information will be synthesized in meta-analyses and narratives. We intend to assess heterogeneity using metaregression (for indication, outcome, and time points) and I2 statistics. Binary outcomes will be expressed as odds ratios, and continuous outcomes as standardized mean differences. Effect measures will be provided using 95% confidence intervals. We plan sensitivity analyses to assess methodological quality, outcome reporting etc., and subgroup analyses on age, dosage, and duration of treatment. Discussion: We will quantify the frequency of anticholinergic and other ADRs/ADEs in adults taking amitriptyline for any indication by comparing rates for amitriptyline vs. placebo, hence, preventing bias from disease symptoms and nocebo effects. As no standardized instrument exists to measure it, our overall estimate of anticholinergic ADRs may have limitations.
Background: Essential Tremor (ET) is a progressive neurological disorder characterized by postural and kinetic tremor most commonly affecting the hands and arms. Medically intractable ET can be treated by deep brain stimulation (DBS) of the ventral intermediate nucleus of thalamus (VIM). We investigated whether the location of the effective contact (most tremor suppression with at least side effects) in VIM-DBS for ET changes over time, indicating a distinct mechanism of loss of efficacy that goes beyond progression of tremor severity, or a mere reduction of DBS efficacy.
Methods: We performed programming sessions in 10 patients who underwent bilateral vim-DBS surgery between 2009 and 2017 at our department. In addition to the intraoperative (T1) and first clinical programming session (T2) a third programming session (T3) was performed to assess the effect- and side effect threshold (minimum voltage at which a tremor suppression or side effects occurred). Additionally, we compared the choice of the effective contact between T1 and T2 which might be affected by a surgical induced “brain shift.”
Discussion: Over a time span of about 4 years VIM-DBS in ET showed continuous efficacy in tremor suppression during stim-ON compared to stim-OFF. Compared to immediate postoperative programming sessions in ET-patients with DBS, long-term evaluationshowednorelevantchangeinthechoiceofcontactwithrespecttosideeffects andefficacy.InthemajorityofthecasestheactivecontactatT2didnotcorrespondtothe most effective intraoperative stimulation site T1, which might be explained by a brain-shift due to cerebral spinal fluid loss after neurosurgical procedure.
This case series assessed a commercial airline flight from Tel Aviv, Israel, to Frankfurt, Germany, that occurred on March 9th, 2020. Among 102 passengers on a Boeing 737-900 aircraft were 24 members of a tourist group. Starting 7 days earlier, the group had contact with a hotel manager who later received a diagnosis of coronavirus disease 2019 (COVID-19). No member of the group had received a diagnosis of COVID-19 before the flight, and no measures to prevent transmission (eg, wearing of masks) had been applied. The flight duration was 4 hours 40 minutes.
MicroRNA miR-181 - a rheostat for TCR signaling in thymic selection and peripheral T-Cell function
(2020)
The selection of T cells during intra-thymic d evelopment is crucial to obtain a functional and simultaneously not self-reactive peripheral T cell repertoire. However, selection is a complex process dependent on T cell receptor (TCR) thresholds that remain incompletely understood. In peripheral T cells, activation, clonal expansion, and contraction of the active T cell pool, as well as other processes depend on TCR signal strength. Members of the microRNA (miRNA) miR-181 family have been shown to be dynamically regulated during T cell development as well as dependent on the activation stage of T cells. Indeed, it has been shown that expression of miR-181a leads to the downregulation of multiple phosphatases, implicating miR-181a as ‘‘rheostat’’ of TCR signaling. Consistently, genetic models have revealed an essential role of miR-181a/b-1 for the generation of unconventional T cells as well as a function in tuning TCR sensitivity in peripheral T cells during aging. Here, we review these broad roles of miR-181 family members in T cell function via modulating TCR signal strength.
With obesity having doubled in the last decade, hypertension is on the rise. In one-third of hypertensive patients the metabolic syndrome is present. This might be one factor for the increasing number of prescriptions for angiotensin receptor blockers and calcium-channel blockers besides a more favorable risk-to-benefit ratio. The aim of the present study was to evaluate a therapeutic drug monitoring (TDM) method for assessment of adherence based on cut-offs in inpatients and to compare it to an established urine drug screening in outpatients. A method for quantification of calcium-channel blockers and angiotensin receptor blockers using high-performance liquid chromatography-tandem mass spectrometric analysis (LC-MS/MS) was developed and validated. The method was applied to serum samples of 32 patients under supervised medication to establish cut-off values for adherence assessment based on dose-related concentrations (DRC, calculated from pharmacokinetic data). Furthermore, corresponding urine and blood samples of 42 outpatients without supervised medication were analysed and the results compared with regard to adherence assessment. All serum concentrations measured for amlodipine (n = 40), lercanidipine (n = 14), candesartan (n = 10), telmisartan (n = 4) and valsartan (n = 10) in inpatients were above the patient specific lower DRC confirming adherence. Of 42 outpatients the identification of analytes in urine as well as the quantification in serum exhibited differing results. According to urinalysis, adherence was demonstrated in only 87.0% of prescriptions, compared to 91.3% for serum analyses. Differences were observed for amlodipine, lercanidipine and candesartan which can be explained by a higher specificity of the serum analysis approach due to pharmacokinetics. The present study confirms that assessing adherence based on serum drug concentrations with individually calculated lower DRCs is more accurate than using qualitative urine analysis. In particular, drugs with low bioavailability, low renal excretion or high metabolism rate such as lercanidipine and candesartan may lead to underestimation of adherence via urine analysis.
Emerging evidence suggests a complex relationship between sphingosine 1-phosphate (S1P) signaling and stroke. Here, we show the kinetics of S1P in the acute phase of ischemic stroke and highlight accompanying changes in immune cells and S1P receptors (S1PR). Using a C57BL/6 mouse model of middle cerebral artery occlusion (MCAO), we assessed S1P concentrations in the brain, plasma, and spleen. We found a steep S1P gradient from the spleen towards the brain. Results obtained by qPCR suggested that cells expressing the S1PR type 1 (S1P1+) were the predominant population deserting the spleen. Here, we report the cerebral recruitment of T helper (TH) and regulatory T (TREG) cells to the ipsilateral hemisphere, which was associated with differential regulation of cerebral S1PR expression patterns in the brain after MCAO. This study provides insight that the S1P-S1PR axis facilitates splenic T cell egress and is linked to the cerebral recruitment of S1PR+ TH and TREG cells. Further insights by which means the S1P-S1PR-axis orchestrates neuronal positioning may offer new therapeutic perspectives after ischemic stroke.
Background: Many patients suffering from exercise-induced asthma (EIA) have normal lung function at rest and show symptoms and a decline in FEV1 when they do sports or during exercise-challenge. It has been described that long-chain polyunsaturated fatty acids (LCPUFA) could exert a protective effect on EIA.
Methods: In this study the protective effect of supplementation with a special combination of n-3 and n-6 LCPUFA (sc-LCPUFA) (total 1.19 g/ day) were investigated in an EIA cold air provocation model. Primary outcome measure: Decrease in FEV1 after exercise challenge and secondary outcome measure: anti-inflammatory effects monitored by exhaled NO (eNO) before and after sc-LCPUFA supplementation versus placebo.
Results: Ninety-nine patients with exercise-induced symptoms aged 10 to 45 were screened by a standardized exercise challenge in a cold air chamber at 4 °C. Seventy-three patients fulfilled the inclusion criteria of a FEV1 decrease > 15% and were treated double-blind placebo-controlled for 4 weeks either with sc-LCPUFA or placebo. Thirty-two patients in each group completed the study. Mean FEV1 decrease after cold air exercise challenge and eNO were unchanged after 4 weeks sc-LCPUFA supplementation.
Conclusion: Supplementation with sc-LCPUFA at a dose of 1.19 g/d did not have any broncho-protective and anti-inflammatory effects on EIA.
Trial registration: Clinical trial registration number: NCT02410096. Registered 7 February 2015 at Clinicaltrial.gov
SARS-CoV-2 is the causative agent of COVID-19. Severe COVID-19 disease has been associated with disseminated intravascular coagulation and thrombosis, but the mechanisms underlying COVID-19-related coagulopathy remain unknown. The risk of severe COVID-19 disease is higher in males than in females and increases with age. To identify gene products that may contribute to COVID-19-related coagulopathy, we analyzed the expression of genes associated with the Gene Ontology (GO) term “blood coagulation” in the Genotype-Tissue Expression (GTEx) database and identified four procoagulants, whose expression is higher in males and increases with age (ADAMTS13, F11, HGFAC, KLKB1), and two anticoagulants, whose expression is higher in females and decreases with age (C1QTNF1, SERPINA5). However, the expression of none of these genes was regulated in a proteomics dataset of SARS-CoV-2-infected cells and none of the proteins have been identified as a binding partner of SARS-CoV-2 proteins. Hence, they may rather generally predispose individuals to thrombosis without directly contributing to COVID-19-related coagulopathy. In contrast, the expression of the procoagulant transferrin (not associated to the GO term “blood coagulation”) was higher in males, increased with age, and was upregulated upon SARS-CoV-2 infection. Hence, transferrin warrants further examination in ongoing clinic-pathological investigations.
miR-142-3p expression is predictive for severe traumatic brain injury (TBI) in trauma patients
(2020)
Background: Predictive biomarkers in biofluids are the most commonly used diagnostic method, but established markers in trauma diagnostics lack accuracy. This study investigates promisingmicroRNAs(miRNA)releasedfromaffectedtissueafterseveretraumathathavepredictive values for the effects of the injury.
Methods: A retrospective analysis of prospectively collected data and blood samples of n = 33 trauma patients (ISS≥16) is provided. Levels of miR-9-5p, -124-3p, -142-3p, -219a-5p, -338-3pand-423-3p inseverelyinjuredpatients (PT)withouttraumatic braininjury (TBI) or with severe TBI (PT + TBI) and patients with isolated TBI (isTBI) were measured within 6 h after trauma.
Results: The highest miR-423-3p expression was detected in patients with severe isTBI, followed by patients with PT + TBI, and lowest levels were found in PT patients without TBI (2−∆∆Ct,p = 0.009). ApositivecorrelationbetweenmiR-423-3plevelandincreasingAIShead (p = 0.001) and risk of mortality (RISC II, p = 0.062) in trauma patients (n = 33) was found. ROC analysis of miR-423-3p levels revealed them as statistically significant to predict the severity of brain injury in trauma patients (p = 0.006). miR-124-3p was only found in patients with severe TBI, miR-338-3p was shown in all trauma groups. miR-9-5p, miR-142-3p and miR-219a-5p could not be detected in any of the four groups. Conclusion: miR-423-3p expression is significantly elevated after isolated traumatic braininjuryandpredictableforsevereTBIinthefirsthoursaftertrauma. miR-423-3pcouldrepresent a promising new biomarker to identify severe isolated TBI.
A message from the human placenta: structural and immunomodulatory defense against SARS-CoV-2
(2020)
The outbreak of the coronavirus disease 2019 (COVID-19) pandemic has caused a global public health crisis. Viral infections may predispose pregnant women to a higher rate of pregnancy complications, including preterm births, miscarriage and stillbirth. Despite reports of neonatal COVID-19, definitive proof of vertical transmission is still lacking. In this review, we summarize studies regarding the potential evidence for transplacental transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterize the expression of its receptors and proteases, describe the placental pathology and analyze virus-host interactions at the maternal-fetal interface. We focus on the syncytium, the barrier between mother and fetus, and describe in detail its physical andstructuraldefenseagainstviralinfections. Wefurtherdiscussthepotentialmolecularmechanisms, whereby the placenta serves as a defense front against pathogens by regulating the interferon type III signaling, microRNA-triggered autophagy and the nuclear factor-κB pathway. Based on these data, we conclude that vertical transmission may occur but rare, ascribed to the potent physical barrier, the fine-regulatedplacentalimmunedefenseandmodulationstrategies. Particularly,immunomodulatory mechanismsemployedbytheplacentamaymitigateviolentimmuneresponse,maybesoftencytokine storm tightly associated with severely ill COVID-19 patients, possibly minimizing cell and tissue damages, and potentially reducing SARS-CoV-2 transmission.
Chronic treatment with the mTOR inhibitor, everolimus, fails long-term in preventing tumor growth and dissemination in cancer patients. Thus, patients experiencing treatment resistance seek complementary measures, hoping to improve therapeutic efficacy. This study investigated metastatic characteristics of bladder carcinoma cells exposed to everolimus combined with the isothiocyanate sulforaphane (SFN), which has been shown to exert cancer inhibiting properties. RT112, UMUC3, or TCCSUP bladder carcinoma cells were exposed short- (24 h) or long-term (8 weeks) to everolimus (0.5 nM) or SFN (2.5 µM), alone or in combination. Adhesion and chemotaxis along with profiling details of CD44 receptor variants (v) and integrin α and β subtypes were evaluated. The functional impact of CD44 and integrins was explored by blocking studies and siRNA knock-down. Long-term exposure to everolimus enhanced chemotactic activity, whereas long-term exposure to SFN or the SFN-everolimus combination diminished chemotaxis. CD44v4 and v7 increased on RT112 cells following exposure to SFN or SFN-everolimus. Up-regulation of the integrins α6, αV, and β1 and down-regulation of β4 that was present with everolimus alone could be prevented by combining SFN and everolimus. Down-regulation of αV, β1, and β4 reduced chemotactic activity, whereas knock-down of CD44 correlated with enhanced chemotaxis. SFN could, therefore, inhibit resistance-related tumor dissemination during everolimus-based bladder cancer treatment.
Depletion of yeast/fly Ataxin-2 rescues TDP-43 overexpression toxicity. In mouse models of Amyotrophic Lateral Sclerosis via TDP-43 overexpression, depletion of its ortholog ATXN2 mitigated motor neuron degeneration and extended lifespan from 25 days to >300 days. There is another ortholog in mammals, named ATXN2L (Ataxin-2-like), which is almost uncharacterized but also functions in RNA surveillance at stress granules. We generated mice with Crispr/Cas9-mediated deletion of Atxn2l exons 5-8, studying homozygotes prenatally and heterozygotes during aging. Our novel findings indicate that ATXN2L absence triggers mid-gestational embryonic lethality, affecting female animals more strongly. Weight and development stages of homozygous mutants were reduced. Placenta phenotypes were not apparent, but brain histology showed lamination defects and apoptosis. Aged heterozygotes showed no locomotor deficits or weight loss over 12 months. Null mutants in vivo displayed compensatory efforts to maximize Atxn2l expression, which were prevented upon nutrient abundance in vitro. Mouse embryonal fibroblast cells revealed more multinucleated giant cells upon ATXN2L deficiency. In addition, in human neural cells, transcript levels of ATXN2L were induced upon starvation and glucose and amino acids exposure, but this induction was partially prevented by serum or low cholesterol administration. Neither ATXN2L depletion triggered dysregulation of ATXN2, nor a converse effect was observed. Overall, this essential role of ATXN2L for embryogenesis raises questions about its role in neurodegenerative diseases and neuroprotective therapies.
Manufacturing processes of custom implant abutments may contaminate their surfaces with micro wear deposits and generic pollutants. Such particulate debris, if not removed, might be detrimental and provoke inflammatory reactions in peri-implant tissues. Although regulatory guidelines for adequate cleaning, disinfection, or sterilization exist, there does not appear to be a consistent application and data on the amount and extent of such contaminants is lacking. The aim of the present in vitro study was to evaluate the quality and quantity of processing-related surface contamination of computer-aided design/computer-aided manufacturing (CAD/CAM) abutments in the state of delivery and after ultrasonic cleaning. A total of 28 CAD/CAM monotype and hybrid abutments were cleaned and disinfected applying a three-stage ultrasonic protocol (Finevo protocol). Before and after cleaning, the chemical composition and the contamination of the abutments were assessed using scanning electron microscopy (SEM), dispersive X-ray spectroscopy(EDX),andcomputer-aidedplanimetricmeasurement(CAPM).Inthedeliverycondition, monotype abutments showed a significantly higher amount of debris compared to hybrid abutments (4.86±6.10% vs. 0.03 ± 0.03%, p < 0.001). The polishing process applied in the laboratory after bonding the hybrid abutment components reduces the surface roughness and thus contributes substantially to their purity. The extent of contamination caused by computer-aided manufacturing of custom abutments can be substantially minimized using a three-stage ultrasonic protocol.
Alcoholism is one of the leading and increasingly prevalent reasons of liver associated morbidity and mortality worldwide. Alcoholic hepatitis (AH) constitutes a severe disease with currently no satisfying treatment options. Lipoxin A4 (LXA4), a 15-lipoxygenase (ALOX15)-dependent lipid mediator involved in resolution of inflammation, showed promising pre-clinical results in the therapy of several inflammatory diseases. Since inflammation is a main driver of disease progression in alcoholic hepatitis, we investigated the impact of endogenous ALOX15-dependent lipid mediators and exogenously applied LXA4 on AH development. A mouse model for alcoholic steatohepatitis (NIAAA model) was tested in Alox12/15+/+ and Alox12/15−/− mice, with or without supplementation of LXA4. Absence of Alox12/15 aggravated parameters of liver disease, increased hepatic immune cell infiltration in AH, and elevated systemic neutrophils as a marker for systemic inflammation. Interestingly, i.p. injections of LXA4 significantly lowered transaminase levels only in Alox12/15−/− mice and reduced hepatic immune cell infiltration as well as systemic inflammatory cytokine expression in both genotypes, even though steatosis progressed. Thus, while LXA4 injection attenuated selected parameters of disease progression in Alox12/15−/− mice, its beneficial impact on immunity was also apparent in Alox12/15+/+ mice. In conclusion, pro-resolving lipid mediators may be beneficial to reduce inflammation in alcoholic hepatitis.
Autism spectrum disorders (ASD) are highly heritable and are characterized by deficits in social communication and restricted and repetitive behaviors. Twin studies on phenotypic subdomains suggest a differing underlying genetic etiology. Studying genetic variation explaining phenotypic variance will help to identify specific underlying pathomechanisms. We investigated the effect of common variation on ASD subdomains in two cohorts including >2500 individuals. Based on the Autism Diagnostic Interview-Revised (ADI-R), we identified and confirmed six subdomains with a SNP-based genetic heritability h2SNP = 0.2–0.4. The subdomains nonverbal communication (NVC), social interaction (SI), and peer interaction (PI) shared genetic risk factors, while the subdomains of repetitive sensory-motor behavior (RB) and restricted interests (RI) were genetically independent of each other. The polygenic risk score (PRS) for ASD as categorical diagnosis explained 2.3–3.3% of the variance of SI, joint attention (JA), and PI, 4.5% for RI, 1.2% of RB, but only 0.7% of NVC. We report eight genome-wide significant hits—partially replicating previous findings—and 292 known and novel candidate genes. The underlying biological mechanisms were related to neuronal transmission and development. At the SNP and gene level, all subdomains showed overlap, with the exception of RB. However, no overlap was observed at the functional level. In summary, the ADI-R algorithm-derived subdomains related to social communication show a shared genetic etiology in contrast to restricted and repetitive behaviors. The ASD-specific PRS overlapped only partially, suggesting an additional role of specific common variation in shaping the phenotypic expression of ASD subdomains.
Recent studies suggested an important contribution of sphingosine-1-phospate (S1P) signaling via its specific receptors (S1PRs) in the production of pro-inflammatory mediators such as Interleukin (IL)-1β in cancer and inflammation. In an inflammation-driven cancer setting, we previously reported that myeloid S1PR1 signaling induces IL-1β production by enhancing NLRP3 (NOD-, LRR- and Pyrin Domain-Containing Protein 3) inflammasome activity. However, the autocrine role of S1P and enzymes acting on the S1P rheostat in myeloid cells are unknown. Using human and mouse macrophages with pharmacological or genetic intervention we explored the relative contribution of sphingosine kinases (SPHKs) in NLRP3 inflammasome activity regulation. We noticed redundancy in SPHK1 and SPHK2 activities towards macrophage NLRP3 inflammasome transcriptional induction and IL-1β secretion. However, pharmacological blockade of both kinases in unison completely abrogated NLRP3 inflammasome induction and IL-1β secretion. Interestingly, human and mouse macrophages demonstrate varied responses towards SPHKs inhibition and IL-1β secretion. Clinical datasets of renal cell carcinoma and psoriasis patients showed a positive correlation between enzymes affecting the S1P rheostat with NLRP3 inflammasome components expression, which corroborates our finding. Our data provide a better understanding on the role of SPHKs and de novo synthesized S1P in macrophage NLRP3 inflammasome activation